StockNews.AI
ALXO
StockNews.AI
173 days

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

1. ALX Oncology plans to report Q4 and full year 2024 results on March 6, 2025. 2. No teleconference will be held with the financial results release. 3. Evorpacept is ALXO's lead candidate, showing promise in immuno-oncology. 4. Ongoing clinical trials are underway for evorpacept across various cancer types.

Earnings
+2.83%Current Return
VS
-1.21%S&P 500
$1.0602/27 08:07 AM EDTEvent Start
$1.0902/28 02:46 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report has potential but lacks immediate catalysts, similar to Pfizer’s Q4 announcements that led to stagnant short-term stock movements.

How important is it?

The financial results could lead to adjustments in valuations based on performance expectations, especially amid a rising focus on immuno-oncology.

Why Short Term?

Q4 results may cause immediate but fleeting price reactions; long-term implications depend on trial outcomes.

Related Companies

PFEJNJBMY
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.  The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Investor Relations Contact:Elhan Webb, CFA, IR Consultantewebb@alxoncology.com Media Contact: Audra Friis, Sam Brown, Inc.audrafriis@sambrown.com (917) 519-9577

Related News